After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
TheStreet highlights 3 stocks pushing the health care sector lower today.
When your top line declines, it's harder to convince investors it's okay to wait years see if a partnership in an early-stage biotech company delivers a home-run drug.
Anheuser-Busch increases its offer for SABMiller after Brexit while the Federal Reserve prepares for action against Goldman Sachs.
Celgene will not seek approval for Revlimid as a maintenance therapy for patients with diffuse large B-cell lymphoma based on the lack of a survival benefit in a clinical trial.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.